Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516374 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

Alzheimer's disease and Abeta peptide. Edition No. 1

VDM Publishing House, March 2010, Pages: 92


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Results presented in this book showed that mutating Ile41 and Ala42 to hydrophilic residues increases solubility, while mutating the same residues to hydrophobic residues enhances the aggregation propensity. This result suggests that the enhanced aggregation propensity of Abeta42 relative to Abeta40 results from the hydrophobic nature of Ile41 and Ala42 residues (Chapter 2). Fusions of GFP to Abeta mutants containing 8~12 mutations of hydrophobic residues to other hydrophobic residues produced white phenotypes, suggesting that generic hydrophobicity (rather than specific nonpolar side chains) at key positions is sufficient to promote aggregation of Abeta42 (Chapter 3). Sequence analysis of Abeta40 mutants with enhanced aggregation propensities indicated that an overall increase in hydrophobicity caused increased aggregation (Chapter 4). Finally, a library of compounds was screened using the Abeta-GFP fusion to identify drug leads that inhibit aggregation of Abeta (Chapter 5). The inhibitory activities of the molecules screened using the Abeta-GFP fusion were confirmed using a series of biophysical techniques.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds